125 related articles for article (PubMed ID: 19229815)
1. Myeloma kidney: toward its prevention--with new insights from in vitro and in vivo models of renal injury.
Sengul S; Li M; Batuman V
J Nephrol; 2009; 22(1):17-28. PubMed ID: 19229815
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases.
Li M; Maderdrut JL; Lertora JJ; Arimura A; Batuman V
Regul Pept; 2008 Jan; 145(1-3):24-32. PubMed ID: 17935800
[TBL] [Abstract][Full Text] [Related]
3. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study.
Li M; Maderdrut JL; Lertora JJ; Batuman V
Peptides; 2007 Sep; 28(9):1891-5. PubMed ID: 17582655
[TBL] [Abstract][Full Text] [Related]
4. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury.
Arimura A; Li M; Batuman V
Blood; 2006 Jan; 107(2):661-8. PubMed ID: 16204306
[TBL] [Abstract][Full Text] [Related]
5. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
6. Proximal tubular injury in myeloma.
Batuman V
Contrib Nephrol; 2007; 153():87-104. PubMed ID: 17075225
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis of acute kidney impairment in patients with multiple myeloma.
Batuman V
Adv Chronic Kidney Dis; 2012 Sep; 19(5):282-6. PubMed ID: 22920637
[TBL] [Abstract][Full Text] [Related]
8. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38.
Arimura A; Li M; Batuman V
Ann N Y Acad Sci; 2006 Jul; 1070():1-4. PubMed ID: 16888145
[TBL] [Abstract][Full Text] [Related]
9. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy.
Ronco P; Plaisier E; Mougenot B; Aucouturier P
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1342-50. PubMed ID: 17699367
[TBL] [Abstract][Full Text] [Related]
11. Crystalloid deposits in the kidney.
Keller LS; Faull RJ; Smith P; Swift J; Bannister KM; Otto S; Peh CA
Nephrology (Carlton); 2005 Feb; 10(1):81-3. PubMed ID: 15705186
[TBL] [Abstract][Full Text] [Related]
12. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
Cserti C; Haspel R; Stowell C; Dzik W
Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
[TBL] [Abstract][Full Text] [Related]
13. [Kidney damage in multiple myeloma and other monoclonal gammopathies].
Adam Z; Pour L; Krejcí M; Stĕpánková S; Svobodová I; Veselý K; Hájek R
Vnitr Lek; 2008 Sep; 54(9):847-61. PubMed ID: 18924346
[TBL] [Abstract][Full Text] [Related]
14. [The treatment of renal failure in multiple myeloma].
Adam Z; Krejcí M; Tichý M; Stepánková S; Pour L; Hájek R
Vnitr Lek; 2009 Jun; 55(6):570-82. PubMed ID: 19662889
[TBL] [Abstract][Full Text] [Related]
15. Myeloma kidney: pathogenesis and treatment.
Basić-Jukić N; Kes P; Labar B
Acta Med Croatica; 2001; 55(4-5):169-75. PubMed ID: 12398020
[TBL] [Abstract][Full Text] [Related]
16. Acute renal failure and myeloma.
Mallick NP
Nephrol Dial Transplant; 1994; 9 Suppl 4():108-10. PubMed ID: 7800241
[No Abstract] [Full Text] [Related]
17. Management of complications in multiple myeloma.
Terpos E; Cibeira MT; Blade J; Ludwig H
Semin Hematol; 2009 Apr; 46(2):176-89. PubMed ID: 19389501
[TBL] [Abstract][Full Text] [Related]
18. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury.
Ying WZ; Li X; Rangarajan S; Feng W; Curtis LM; Sanders PW
J Clin Invest; 2019 Jun; 129(7):2792-2806. PubMed ID: 31205024
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
